menu
    • menu
    [{"orgOrder":0,"company":"AmbioPharm","sponsor":"Adalvo","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"AmbioPharm \/ AmbioPharm","highestDevelopmentStatusID":"1","companyTruncated":"AmbioPharm \/ AmbioPharm"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"Upsher-Smith Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Partnership","leadProduct":"Corticotropin","moa":"ACTH","graph1":"Neurology","graph2":"Approved","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AmbioPharm \/ Upsher-Smith Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"AmbioPharm \/ Upsher-Smith Laboratories"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Thrixopelma pruriens venom peptide","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AmbioPharm \/ AmbioPharm","highestDevelopmentStatusID":"1","companyTruncated":"AmbioPharm \/ AmbioPharm"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"Adalvo","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"AmbioPharm \/ AmbioPharm","highestDevelopmentStatusID":"12","companyTruncated":"AmbioPharm \/ AmbioPharm"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"ONL Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ONL1204","moa":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AmbioPharm \/ ONL Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"AmbioPharm \/ ONL Therapeutics"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"Amytrx Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Partnership","leadProduct":"AMTX-100","moa":"NF-kB","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"AmbioPharm \/ AmbioPharm","highestDevelopmentStatusID":"7","companyTruncated":"AmbioPharm \/ AmbioPharm"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"OKYO Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"OK-101","moa":"ChemR23","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"AmbioPharm \/ AmbioPharm","highestDevelopmentStatusID":"8","companyTruncated":"AmbioPharm \/ AmbioPharm"}]

    Find Clinical Drug Pipeline Developments & Deals by AmbioPharm

    Menu

    AmbioPharm

    EVENTS

    • Webinars & Exhibitions

    VIDEO(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    AmbioPharm

    U.S.A arrow
    Conjugates Summit
    Not Confirmed

    AmbioPharm

    U.S.A arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : OK-101

    Therapeutic Area : Ophthalmology

    Study Phase : Preclinical

    Recipient : OKYO Pharma

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to Treat Dry Eye Disease with Subsequent Phase 2 Initiation Alo...

    Details : The OK-101 drug candidate displays potent anti-inflammatory activity in animal models of DED. OK-101 also reduces Corneal Neuropathic Pain (CNP) in a ciliary nerve ligation animal model of CNP.

    Product Name : OK-101

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    August 30, 2022

    Lead Product(s) : OK-101

    Therapeutic Area : Ophthalmology

    Highest Development Status : Preclinical

    Recipient : OKYO Pharma

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    AmbioPharm

    U.S.A arrow
    Conjugates Summit
    Not Confirmed

    AmbioPharm

    U.S.A arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : AMTX-100

    Therapeutic Area : Dermatology

    Study Phase : Phase I/ Phase II

    Recipient : Amytrx Therapeutics

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Amytrx Therapeutics Partners With AmbioPharm to Expand the Potential of Its Breakthrough Leukocyte-Targeting A...

    Details : Amytrx has identified new opportunities for other inflammatory and metabolic diseases with attractive out-licensing and collaborative opportunities using its proprietary AMTX-100 human peptide platform.

    Product Name : AMTX-100

    Product Type : Peptide

    Upfront Cash : Undisclosed

    July 26, 2022

    Lead Product(s) : AMTX-100

    Therapeutic Area : Dermatology

    Highest Development Status : Phase I/ Phase II

    Recipient : Amytrx Therapeutics

    Deal Size : Undisclosed

    Deal Type : Partnership

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    AmbioPharm

    U.S.A arrow
    Conjugates Summit
    Not Confirmed

    AmbioPharm

    U.S.A arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : ONL1204

    Therapeutic Area : Ophthalmology

    Study Phase : IND Enabling

    Sponsor : ONL Therapeutics

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    AmbioPharm Supports ONL Therapeutics with Peptide Manufacturing to Prepare for IND Application for Phase 2 Stu...

    Details : ONL1204 Ophthalmic Solution is a novel, first-in-class small peptide Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs in a range of retinal diseases and conditions.

    Product Name : ONL1204

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    July 12, 2022

    Lead Product(s) : ONL1204

    Therapeutic Area : Ophthalmology

    Highest Development Status : IND Enabling

    Sponsor : ONL Therapeutics

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    AmbioPharm

    U.S.A arrow
    Conjugates Summit
    Not Confirmed

    AmbioPharm

    U.S.A arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Icatibant Acetate

    Therapeutic Area : Genetic Disease

    Study Phase : Approved

    Recipient : Adalvo

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Adalvo Announces Successful DCP Closure for Icatibant

    Details : Icatibant, a complex injectable peptide product, forming part of high-value product, is an equivalent and more affordable version of Firazyr (Takeda/Shire), used used to treat a serious orphan disease, acute attacks of hereditary angioedema.

    Product Name : Icatibant Acetate-Generic

    Product Type : Peptide

    Upfront Cash : Not Applicable

    September 28, 2021

    Lead Product(s) : Icatibant Acetate

    Therapeutic Area : Genetic Disease

    Highest Development Status : Approved

    Recipient : Adalvo

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    AmbioPharm

    U.S.A arrow
    Conjugates Summit
    Not Confirmed

    AmbioPharm

    U.S.A arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Thrixopelma pruriens venom peptide

    Therapeutic Area : Neurology

    Study Phase : Undisclosed

    Recipient : University of California

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    AmbioPharm Inc. Working with University of California Davis to Develop Non-Opioid Peptide-Based Pain Therapeut...

    Details : Researchers have utilized a venom peptide originally isolated from the Peruvian green velvet tarantula (Thrixopelma pruriens) that blocks Nav1.7 voltage-gated ion channels, an ion channel important in pain signaling.

    Product Name : Undisclosed

    Product Type : Peptide

    Upfront Cash : Not Applicable

    July 20, 2021

    Lead Product(s) : Thrixopelma pruriens venom peptide

    Therapeutic Area : Neurology

    Highest Development Status : Undisclosed

    Recipient : University of California

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    AmbioPharm

    U.S.A arrow
    Conjugates Summit
    Not Confirmed

    AmbioPharm

    U.S.A arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Corticotropin

    Therapeutic Area : Neurology

    Study Phase : Approved

    Sponsor : Upsher-Smith Laboratories

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Upsher-Smith and AmbioPharm Announce Partnership Agreement to Develop and Market Corticotropin Injection

    Details : AmbioPharm will manufacture the active pharmaceutical ingredient exclusively for Upsher-Smith. A contract manufacturing organization will exclusively supply Upsher-Smith with the finished product for sale in the United States.

    Product Name : Acthar

    Product Type : Peptide

    Upfront Cash : Undisclosed

    August 07, 2020

    Lead Product(s) : Corticotropin

    Therapeutic Area : Neurology

    Highest Development Status : Approved

    Sponsor : Upsher-Smith Laboratories

    Deal Size : Undisclosed

    Deal Type : Partnership

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    AmbioPharm

    U.S.A arrow
    Conjugates Summit
    Not Confirmed

    AmbioPharm

    U.S.A arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Endocrinology

    Study Phase : Undisclosed

    Recipient : Adalvo

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Adalvo and AmbioPharm Partner on Development & Licensing for Key Peptide Product

    Details : The partnership includes a basket of difficult-to-make peptide products that will be used to treat various diseases, ranging from diabetes to immunology disorders, cardiologic and endocrinology diseases.

    Product Name : Undisclosed

    Product Type : Peptide

    Upfront Cash : Undisclosed

    July 29, 2020

    Lead Product(s) : Undisclosed

    Therapeutic Area : Endocrinology

    Highest Development Status : Undisclosed

    Recipient : Adalvo

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth